Headache News and Research

Latest Headache News and Research

Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Data from a retrospective pooled analysis of eight phase III trials (two 18-week and six 24-week) of linagliptin 5 mg once-daily, showed reductions from baseline A1c at 18 (eight trials) and 24 (six trials) weeks compared to placebo in African-American adults with type 2 diabetes (T2D),

16 May 2014

Tips to prevent sunburn and reduce risk of skin cancer

While warmer weather means more outdoor activities, it also means carefully protecting your skin from the sun.

14 May 2014

Pfizer reports positive results from rLP2086 Phase 2 study for invasive meningococcal disease

Pfizer Inc. announced today the results from two Phase 2 studies of bivalent rLP2086, Pfizer's recombinant vaccine candidate, currently under development for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B in 10 to 25 year olds.

12 May 2014

Triple therapy shows promise for severe PAH

Results of a small pilot study among patients with severe pulmonary arterial hypertension support the long-term benefits of upfront triple combination therapy, French researchers report.

7 May 2014

Social worker has potential to reduce functional decline of people with mild traumatic brain injury

More than a million people are treated for mild traumatic brain injuries in U.S. hospitals and emergency rooms each year. Yet few receive appropriate psychological and social follow-up care that can make the difference in whether or not they fully recover.

7 May 2014

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor® LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.

6 May 2014

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb Company today announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer (NSCLC) and metastatic renal cell carcinoma (mRCC) will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 30-June 3.

6 May 2014

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA).

6 May 2014

Headaches an occupational hazard astronauts

Headaches in astronauts on the International Space Station (ISS) are attributed to elevated levels of carbon dioxide (CO2), reports a study in the May Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM).

1 May 2014

Migraine a depressing issue in bipolar disorder

Patients with bipolar disorder have a markedly increased prevalence of migraine, report researchers.

1 May 2014

GE Healthcare announces commercial availability of new Alzheimer’s diagnostic tool

GE Healthcare today announced the first seven markets where Vizamyl (Flutemetamol F18 injection), a radioactive diagnostic agent approved by the FDA will be available. Late in the second quarter of 2014, Vizamyl will be available to imaging centers near East Rutherford, NJ, Woburn, MA, Beltsville, MD, East Lansing, MI, Dallas, TX, Phoenix, AZ and Colton, CA.

29 Apr 2014

Professor offers water-safety tips to prevent young children from getting sick

There is nothing better on a hot, summer day than a refreshing dip in a community pool, water park, lake or ocean. However, bacteria and parasites can lurk in all kinds of water and put a real damper on summertime fun unless people practice a few, simple safety tips.

29 Apr 2014

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has entered into a license agreement with Intravacc (Institute for Translational Vaccinology) from The Netherlands to develop and commercialize the Sabin Inactivated Polio Vaccine (sIPV) for distribution to China and other countries.

28 Apr 2014

Highlights from April 2014 issue of Mayo Clinic Health Letter

Here are highlights from the April issue of Mayo Clinic Health Letter.

26 Apr 2014

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation.

23 Apr 2014

Glaucoma drug may help reverse obesity-related vision loss in women

An inexpensive glaucoma drug, when added to a weight loss plan, can improve vision for women with a disorder called idiopathic intracranial hypertension (IIH), according to a study funded by the National Institutes of Health.

23 Apr 2014

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.

23 Apr 2014

FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

The US Food and Drug Administration has announced the expanded approval of Arzerra (ofatumumab) in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukemia (CLL). Arzerra was previously approved by the FDA in October 2009 for the treatment of CLL resistant to other forms of chemotherapy. Diplomat has access to dispense Arzerra.

22 Apr 2014

Scientists lay groundwork for understanding immune responses in Lyme disease patients

A team of scientists led by Johns Hopkins and Stanford University researchers has laid the groundwork for understanding how variations in immune responses to Lyme disease can contribute to the many different outcomes of this bacterial infection seen in individual patients. A report on the work appears online April 16 in PLOS One.

21 Apr 2014

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

GlaxoSmithKline plc and Genmab A/S announced today that the U.S. Food and Drug Administration (FDA) has approved a Supplemental Biologic License Application (sBLA) for the use of Arzerra® (ofatumumab), a CD20-directed cytolytic monoclonal antibody, in combination with chlorambucil for the treatment of previously untreated patients with chronic lymphocytic leukaemia (CLL) for whom fludarabine-based therapy is considered inappropriate.

21 Apr 2014

Headache News and Research

Latest Headache News and Research

Data from phase III trials supports safety, efficacy of linagliptin in treating T2D in African-American adults

Tips to prevent sunburn and reduce risk of skin cancer

Pfizer reports positive results from rLP2086 Phase 2 study for invasive meningococcal disease

Triple therapy shows promise for severe PAH

Social worker has potential to reduce functional decline of people with mild traumatic brain injury

Novartis presents Phase III results of Signifor LAR therapy in patients with acromegaly

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Headaches an occupational hazard astronauts

Migraine a depressing issue in bipolar disorder

GE Healthcare announces commercial availability of new Alzheimer’s diagnostic tool

Professor offers water-safety tips to prevent young children from getting sick

Sinovac Biotech commits to commercialize Sabin Inactivated Polio Vaccine in China

Highlights from April 2014 issue of Mayo Clinic Health Letter

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Glaucoma drug may help reverse obesity-related vision loss in women

Pfizer reports positive results from two tofacitinib Phase 3 trials for moderate-to-severe plaque psoriasis

FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

Scientists lay groundwork for understanding immune responses in Lyme disease patients

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Headache News and Research

Latest Headache News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in